Key Drivers
- High Profitability
- Weak Balance Sheet
- Rich Valuation
AIAI Summary
ABBV has evolved into a multi-engine growth and cash-flow story, but the near-term investment case hinges on whether Skyrizi/Rinvoq and neuroscience can outrun Apogee-driven EPS dilution and debt overhang fast enough to justify the current valuation and break the stock out of consolidation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Profitability
- •Weak Balance Sheet
- •Rich Valuation
ABBV delivers strong margins and cash flow, but the investment case is weighed down by negative equity, weak liquidity, heavy debt, and a rich valuation.
Price Behavior
Key Price Behavior Insights:
- •Mid-240s support
- •Overhead resistance
- •Fragile momentum
ABBV has drifted slightly lower over the last month, holding the $243.80-$246.00 support zone but staying capped below $257.61-$263.58, so the setup remains consolidation rather than a confirmed breakout.
Rebounded to $250.88 on 2026-08-13, then failed to hold gains on 2026-08-14
Sentiment & News
Key News Insights:
- •Strong Q2 sales
- •Lower EPS outlook
- •Dividend support
AbbVie posted strong Q2 growth and lifted revenue guidance, but lower EPS expectations and Apogee-related margin pressure overshadowed the results.
The news is mildly positive for AbbVie's long-term growth story, but near-term share performance may stay capped by profit guidance concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings